-+ 0.00%
-+ 0.00%
-+ 0.00%

IBIO’S FIRST-IN-CLASS ACTIVIN E ANTIBODY ACHIEVES >26% FAT REDUCTION WITHOUT MUSCLE LOSS AND SHOWS SYNERGY WITH GLP-1S IN PRECLINICAL MODEL

Reuters·05/05/2025 12:00:01

Please log in to view news